SOX9 antibody and other transcription factor antibodies: abundance, nucleus and validation

Working with a nuclear target

1. Use a permeabilisation that reaches the nucleus. The detergent and buffer that permeabilise a cytoplasmic protein frequently do not open the nuclear envelope adequately. Nuclear factor protocols use their own buffer systems, and for flow cytometry a dedicated nuclear permeabilisation kit is the practical answer rather than an adjustment.
2. Expect low abundance and plan the amplification. Many of these proteins are present at a small fraction of a structural protein's level, so a direct conjugate may simply not reach. Amplification through a biotinylated intermediate or a polymer detection system is what makes the signal visible, at the cost of harder quantitation.
3. Insist on a genetic negative, because isotype controls are weak here. An isotype control shows the format's background and says nothing about specificity for a nuclear protein at low abundance. A knockout, a knockdown or a cell type known not to express the factor is what separates signal from nuclear background.
4. Know whether the epitope is modification dependent. Several of these targets are read through their modifications, and an antibody against a modified residue will not see the unmodified protein and vice versa. Read the immunogen and ask for the specificity evidence, ideally a peptide array.
5. Match the reagent to the application, not the target. An antibody validated for chromatin immunoprecipitation has been shown to work on fixed, fragmented chromatin, which is a different demonstration from a western blot. Buy against the application you will run and read that application's evidence specifically.

Chromatin immunoprecipitation is a separate qualification

An antibody that detects a factor on a blot may not immunoprecipitate it from fixed, fragmented chromatin, where the epitope is cross-linked and partly buried. Ask for enrichment data at a known target locus and a known negative region.

Lot variation matters more here than almost anywhere else, because most such reagents are polyclonal and the mark or epitope is small. Buy the project's supply as one lot and record it.

Nuclear background and how to reduce it

Nuclei bind antibody non-specifically, and the usual remedies are longer blocking with a protein that is not related to the sample, a more dilute primary with a longer incubation, and a wash regime with detergent. All three help; a stronger antibody concentration does not.

Run the secondary-only control on nuclei specifically. A background that is present without the primary is a detection problem, and no amount of primary titration will fix it.

Reading a result about a factor that moves

Many transcription factors are regulated by translocation rather than by abundance, so a whole-cell measurement can be flat while the biology changes entirely. Fractionate, or image and measure a nuclear to cytoplasmic ratio per cell.

Where translocation is the readout, a per-cell ratio across a population is far more informative than a mean, because the response is frequently a change in the fraction of responding cells rather than a shift in all of them.

Family members that share almost everything

Closely related factors often differ only outside their conserved domains, so the useful immunogens are the divergent termini rather than the functional core. Where a supplier will not say which region the immunogen came from, assume the antibody may see the whole family and design the experiment so that the conclusion still holds if it does.

Where discriminating between family members is the point, the only reliable evidence is your own: cells in which one member has been removed, run beside cells in which another has. It is slower than trusting a datasheet and it is what makes the result survive review, which is why funders now ask how key reagents were authenticated.

A nuclear receptor as the cautionary example

One nuclear receptor in particular has a long published history of antibodies that produced confident and contradictory results between laboratories, later attributed to reagents that were detecting other proteins. A substantial literature had to be re-examined, and the episode is why reviewers now ask for the validation rather than the catalogue number.

The lesson generalises to every scarce nuclear target with a large family: the reagent is part of the experiment and has to be controlled like one. That means a genetic control in your own hands, the lot recorded, and the validation stated in the methods rather than assumed from the product page.

Factors whose amount changes with the clock

Some nuclear targets are regulated on a daily cycle, so the same cells sampled at two times of day genuinely contain different amounts. A single time point cannot distinguish a treatment effect from a phase shift, and comparing conditions harvested at different times produces a difference that has nothing to do with the treatment.

Where a target behaves this way, sample a time course, record the harvest time with every sample, and keep the harvest time constant across conditions. This is a design requirement rather than a reagent one, and no antibody quality compensates for getting it wrong.

A runx1 antibody and the isoforms one locus makes

RUNX1 is transcribed from two promoters into isoforms of different length, and translocations in leukaemia produce fusion proteins, so a runx1 antibody has to say where its epitope lies before a band can be named. A clone against the carboxy terminus misses a fusion that keeps only the amino end. It is nuclear and modest in abundance, so a nuclear extract with its own loading reference is the preparation.

A myod1 antibody and a factor read as a lineage call

MYOD1 marks skeletal muscle commitment and is used in pathology to call a rhabdomyosarcoma, so a myod1 antibody is scored as nuclear positivity in a proportion of cells rather than as an intensity. Cytoplasmic staining is the common artefact and means the retrieval or the dilution is wrong. A muscle containing control on the same slide is what makes a negative interpretable.

A snai1 antibody and a protein with a short half life

SNAI1 is degraded within minutes unless it is stabilised, so a snai1 antibody often reports almost nothing in an untreated cell and a proteasome inhibitor lane is what shows the antibody works at all. Phosphorylation controls both its location and its turnover, which is why a fractionation carries more information than a whole cell blot. Overexpression material is the practical positive control.

An etv4 antibody and a family with shared domains

The ETS factors share a DNA binding domain closely enough that a clone raised on it reports several of them, so an etv4 antibody needs cross reactivity data against ETV1 and ETV5 in particular. Expression is restricted in adult tissue and re-expressed in some tumours, which makes a normal negative and a tumour positive the pair of controls the datasheet should show.

A prox1 antibody and two tissues that read it differently

PROX1 marks lymphatic endothelium in vascular work and is a lineage factor in liver and neural tissue, so a prox1 antibody is interpreted against the tissue rather than on its own. Nuclear staining with a vessel pattern is the lymphatic reading; scattered nuclei in parenchyma is the other. Because the two uses are unrelated, the clone's validated application is what decides which claim it can support.

Common questions

Why can I not detect my transcription factor?

Usually abundance and permeabilisation. These proteins sit far below structural proteins in level and need a nuclear permeabilisation protocol; a cytoplasmic protocol reports absence rather than a low signal.

Is an isotype control enough for a nuclear stain?

No. It shows the background of the reagent format and nothing about specificity at low abundance in a nucleus full of protein. A genetic negative, or a cell type known not to express the factor, is what settles it.

What does a foxp3 antibody flow cytometry panel need that a surface panel does not?

A nuclear fixation and permeabilisation system, applied after the surface markers are stained, and surface markers that survive it. Several surface epitopes are damaged by nuclear permeabilisation buffers.

How do I judge the specificity of epigenetic antibodies?

By evidence that it discriminates between neighbouring modification states, which means a peptide array or a dot blot against a panel of modified peptides, plus a peptide competition you can run yourself.

Can one antibody distinguish between family members?

Only if the immunogen sits in a divergent region and the supplier shows it was tested against the other members. Where that distinction carries the experiment, confirm it in cells lacking each member rather than relying on a single clean band.

Why does my nuclear target give no band at all?

Most often because it was never in the lysate. Chromatin-bound factors need an extraction that releases them, so confirm the fractionation with a nuclear marker before concluding the antibody has failed.

Browse by service class

• Compare Gene synthesis on advertised prices